ArticleDiabetes2025
Concerted Actions of FoxO1 and PPARα in Hepatic Gene Expression and Metabolic Adaptation.
Article in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PPARα activation alleviates lithocholic acid-induced liver injury by inhibiting pyroptosis.Liver research (Beijing, China) · 2026Article
- Cholesterol metabolic rewiring shapes immune remodeling across hepatocarcinogenesis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Several transcription factors regulate the fasting response in liver. They include FoxO1 and FoxO3, CREB, C/EBP α/β, glucocorticoid receptor (GR), peroxisome proliferator-activated receptor-α (PPARα), FoxA2, hepatocyte nuclear factor-α (HNF4α), and others. Genome-wide chromatin occupancy studies revealed an unexpected overlap of FoxO1 and PPARα DNA binding sites at active intergenic and intron enhancers, yet their functional significance remains unknown. To address this gap in knowledge, we conducted molecular interaction analyses of these transcription factors and generated combined hepatocyte-specific ablation of the respective genes. Integrated analysis of hepatic RNA sequencing from these mice by FoxO1 and PPARα chromatin immunoprecipitation sequencing revealed a concerted regulation of glucose metabolism, with additive effects on in vivo glucose tolerance. Synergistic effects on glycogenesis were observed when PPARα was ablated in the absence of FoxO1, particularly following a high-fat diet. Free fatty acids increased following FoxO1 and were normalized by PPARα ablation, while liver triglyceride content increased in PPARα knockouts and was normalized by FoxO1 ablation. The findings highlight a functional relay between FoxO1 and PPRAα, linking insulin signaling with hepatic lipid metabolism, and offer insight into potential therapeutic strategies for metabolic diseases. ARTICLE HIGHLIGHTS: FoxO1 and PPARα share significant DNA binding sites, regulating a coordinated transcriptional network in hepatic metabolism. FoxO1 and PPARα orchestrate distinct yet overlapping roles in gluconeogenesis and fatty acid/lipid metabolism. High-fat diet amplifies the metabolic interplay between FoxO1 and PPARα, with implications for insulin resistance management. Targeting the FoxO1-PPARα interplay offers novel strategies for treating selective insulin resistance and metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.